Trial results from Moderna's (MRNA) melanoma drug sent shares of the healthcare giant soaring throughout the week, though Charles Schwab's Rachel Dashiell sees that strength subsiding for now. She points to bearish trends taking control of the stock and notes key levels to watch for a potential reversal.